Related Experiment Video
Updated: Aug 25, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data
1Eli Lilly & Co. Ltd, Basingstoke, UK. busche_chris@lilly.com
Background:
Most evidence suggesting an association between schizophrenia, antipsychotic medications and diabetes has been based on retrospective studies not controlled for important confounders.
Aims:
To compare diabetogenic risk between antipsychotic medications; and to describe the limitations of current prospective data-sets.
Method:
Systematic review of prospective clinical data.
Results:
No difference in the incidence of glycaemic abnormalities between placebo cohorts and antipsychotic medication cohorts was identified. No significant difference between any of the antipsychotic medications studied in terms of their association with glycaemic abnormalities was identified. Treatment-related weight gain did not appear to increase the risk of developing diabetes.
Conclusions:
Diabetogenic potential ascribed to atypical antipsychotic drugs, resulting from retrospective studies, may be incorrect. Cohort sizes and incomplete sampling must preclude any definitive conclusions. Long-term, large, comparative prospective trials are needed, along with agreement upon glucose measurement of choice.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes I: Introduction
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Oral Hypoglycemic Agents: Biguanides and Glitazones
Type I Diabetes III: Clinical Manifestations